The Benchmark Company maintains its Buy rating and $40 price target on Ceradyne, Inc. CRDN and adjusts earnings forecast as Helmet award is seen as a near-term catalyst which could potentially offset Solar.
According to Benchmark, “The military started First Article Test (FAT) on Ceradyne's Enhanced Combat Helmet (ECH) last week. If all goes well, a contract award is expected in late December or early next year. … Management believes solar could be weaker in Q4, and visibility for next year remains limited. The near-term outlook for the solar industry is challenging, with excess supply relative to demand driving significant margin and price reductions. … We lower our FY11 sales and GAAP EPS to $577 million and $3.10 from $588 million and $3.16 to reflect weakness in solar in Q4.”
CRDN closed at $29.83 per share on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in